Qrem
Tecnología Regenerativa Qrem SL is a Barcelona-based company founded in 2016 specializing in regenerative medicine technology. They develop Lab-in-a-box devices, notably Qrem Cytokine, which produces autologous serum rich in cytokines (SARC) from the patient's own blood to stimulate and accelerate tissue repair. Their patented biological process emulates tissue damage ex vivo to obtain cytokines that modulate regeneration, offering a drug-free, natural activation therapy with no side effects. The technology is designed for easy use in medical consultations without special infrastructure or training, enabling broader access to regenerative therapies. Qrem leads in autologous regenerative therapies with CE-marked medical devices, focusing on musculoskeletal and dermatological conditions. They manage the full value chain from development to commercialization and are engaged in multiple R&D projects funded by public and European sources to advance regenerative treatments and AI diagnostic tools. Their business model is based on selling medical devices and consumables to healthcare providers, aiming to make regenerative therapies accessible and cost-effective at scale.
Qrem
Tecnología Regenerativa Qrem SL is a Barcelona-based company founded in 2016 specializing in regenerative medicine technology. They develop Lab-in-a-box devices, notably Qrem Cytokine, which produces autologous serum rich in cytokines (SARC) from the patient's own blood to stimulate and accelerate tissue repair. Their patented biological process emulates tissue damage ex vivo to obtain cytokines that modulate regeneration, offering a drug-free, natural activation therapy with no side effects. The technology is designed for easy use in medical consultations without special infrastructure or training, enabling broader access to regenerative therapies. Qrem leads in autologous regenerative therapies with CE-marked medical devices, focusing on musculoskeletal and dermatological conditions. They manage the full value chain from development to commercialization and are engaged in multiple R&D projects funded by public and European sources to advance regenerative treatments and AI diagnostic tools. Their business model is based on selling medical devices and consumables to healthcare providers, aiming to make regenerative therapies accessible and cost-effective at scale.